All Stories

  1. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2019, Taylor & Francis

    Dr Jee-Fu Huang, Professor MING-LUNG YU

  2. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

    Article • PLoS Genetics, June 2019, PLOS

    Professor MING-LUNG YU, Professor Izhak Haviv

  3. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study

    Article • BMJ Open, May 2019, BMJ

    Professor MING-LUNG YU

  4. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication

    Article • Journal of Gastroenterology and Hepatology, July 2018, Wiley

    Professor MING-LUNG YU, Dr Jee-Fu Huang

  5. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience

    Article • Alimentary Pharmacology & Therapeutics, May 2018, Wiley

    Professor MING-LUNG YU

  6. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy

    Article • Journal of Gastroenterology and Hepatology, February 2018, Wiley

    Professor MING-LUNG YU, Dr Jee-Fu Huang

  7. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1

    Article • Journal of Gastroenterology and Hepatology, November 2017, Wiley

    MD, Ph.D Jeong JH Heo, Professor MING-LUNG YU

  8. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma

    Article • Liver International, November 2017, Wiley

    Professor MING-LUNG YU, Dr Jee-Fu Huang

  9. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals

    Article • Journal of Gastroenterology and Hepatology, September 2017, Wiley

    Professor MING-LUNG YU

  10. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue

    Article • Liver International, September 2017, Wiley

    Professor MING-LUNG YU

  11. Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens

    Article • Journal of Gastroenterology and Hepatology, July 2017, Wiley

    Professor MING-LUNG YU

  12. Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals

    Article • Expert Opinion on Drug Safety, May 2017, Taylor & Francis

    Professor MING-LUNG YU

  13. Disease severity and erythropoiesis in chronic hepatitis C

    Article • Journal of Gastroenterology and Hepatology, March 2017, Wiley

    Professor MING-LUNG YU

  14. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection

    Article • Journal of Gastroenterology and Hepatology, April 2016, Wiley

    Professor MING-LUNG YU

  15. Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C

    Article • Medicine, April 2015, Wolters Kluwer Health

    Professor MING-LUNG YU

  16. New treatments for HCV: Perspective from Asia

    Article • Clinical Liver Disease, January 2015, Wiley

    Professor MING-LUNG YU